Lisa Li
Associate Director, Early-Stage Partnering Japan, Strategy & Portfolio Development Takeda Pharmaceutical
Seminars
Thursday 10th December 2026
Panel Discussion | Pharma’s Appetite for Innovation: What do Global Partners Seek in Novel Targets and Modalities?
9:30 am
- Which CNS indications and targets hold the greatest promise for investable disease‑modifying therapies?
- What stage and type of data are needed to confidently support safety, target engagement, and MoA of new targets under evaluation?
- Do you prioritize new modalities aligned with in‑house expertise, or are you open to partnering with specialists in novel modalities?
